



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)



GPATCH2 siRNA (m): sc-145679

BACKGROUND

GPATCH2 (G patch domain-containing protein 2) is a 528 amino acid protein that contains one G-patch domain. GPATCH2 is overexpressed in breast cancer tissue, and may have a role in breast cancer cell growth. Existing as two alternatively spliced isoforms, the gene encoding GPATCH2 maps to human chromosome 1q41 and mouse chromosome 1 H5. Spanning around 260 million base pairs, chromosome 1 is the largest human chromosome and comprises 8% of the human genome. There are about 3,000 genes on chromosome 1, and considering the great number of genes there are also a large number of diseases associated with chromosome 1. Notably, the rare aging disease Hutchinson-Gilford progeria is associated with the LMNA gene which encodes Lamin A. Stickler syndrome, Parkinsons, Gaucher disease and Usher syndrome are also associated with chromosome 1.

REFERENCES

1. Eudy, J.D., Weston, M.D., Yao, S., Hoover, D.M., Rehm, H.L., Ma-Edmonds, M., Yan, D., Ahmad, I., Cheng, J.J., Ayuso, C., Cremers, C., Davenport, S., Moller, C., Talmadge, C.B., Beisel, K.W., Tamayo, M., Morton, C.C., et al. 1998. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. *Science* 280: 1753-1757.
2. Tayebi, N., Callahan, M., Madike, V., Stubblefield, B.K., Orvisky, E., Krasnewich, D., Fillano, J.J. and Sidransky, E. 2001. Gaucher disease and parkinsonism: a phenotypic and genotypic characterization. *Mol. Genet. Metab.* 73: 313-321.
3. Gregory, S.G., Barlow, K.F., McLay, K.E., Kaul, R., Swarbreck, D., Dunham, A., Scott, C.E., Howe, K.L., Woodfine, K., Spencer, C.C., Jones, M.C., Gillson, C., Searle, S., Zhou, Y., Kokocinski, F., McDonald, L., Evans, R., et al. 2006. The DNA sequence and biological annotation of human chromosome 1. *Nature* 441: 315-321.
4. Betarbet, R., Anderson, L.R., Gearing, M., Hodges, T.R., Fritz, J.J., Lah, J.J. and Levey, A.I. 2008. Fas-associated factor 1 and Parkinson's disease. *Neurobiol. Dis.* 31: 309-315.
5. Holliday, E.G., Nyholt, D.R., Tirupati, S., John, S., Ramachandran, P., Ramamurti, M., Ramadoss, A.J., Jeyagurunathan, A., Kottiswaran, S., Smith, H.J., Filippich, C., Nertney, D.A., Nancarrow, D.J., et al. 2009. Strong evidence for a novel schizophrenia risk locus on chromosome 1p31.1 in homogeneous pedigrees from Tamil Nadu, India. *Am. J. Psychiatry* 166: 206-215.
6. Balcárková, J., Urbánková, H., Scudla, V., Holzerová, M., Bacovský, J., Indrák, K. and Jarosová, M. 2009. Gain of chromosome arm 1q in patients in relapse and progression of multiple myeloma. *Cancer Genet. Cytogenet.* 192: 68-72.
7. Lin, M.L., Fukukawa, C., Park, J.H., Naito, K., Kijima, K., Shimo, A., Ajiro, M., Nishidate, T., Nakamura, Y. and Katagiri, T. 2009. Involvement of G-patch domain containing 2 overexpression in breast carcinogenesis. *Cancer Sci.* 100: 1443-1450.
8. Yokoi, T., Koide, R., Matsuo, K., Nakagawa, A. and Azuma, N. 2009. Analysis of the vitreous membrane in a case of type 1 Stickler syndrome. *Graefes Arch. Clin. Exp. Ophthalmol.* 247: 715-718.

CHROMOSOMAL LOCATION

Genetic locus: Gpatch2 (mouse) mapping to 1 H5.

PRODUCT

GPATCH2 siRNA (m) is a target-specific 19-25 nt siRNA designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see GPATCH2 shRNA Plasmid (m): sc-145679-SH and GPATCH2 shRNA (m) Lentiviral Particles: sc-145679-V as alternate gene silencing products.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNAses and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

GPATCH2 siRNA (m) is recommended for the inhibition of GPATCH2 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor GPATCH2 gene expression knockdown using RT-PCR Primer: GPATCH2 (m)-PR: sc-145679-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.